Scarica l'app Stockscreener
123.46
2.56%
3.08
Dopo l'orario di chiusura:
123.46
Precedente Chiudi:
$120.38
Aprire:
$120.19
Volume 24 ore:
333.94K
Relative Volume:
1.07
Capitalizzazione di mercato:
$1.77B
Reddito:
$1.30M
Utile/perdita netta:
$-41.72M
Rapporto P/E:
-33.30
EPS:
-3.7071
Flusso di cassa netto:
$-22.82M
1 W Prestazione:
+4.97%
1M Prestazione:
-6.90%
6M Prestazione:
+97.13%
1 anno Prestazione:
+357.77%
Intervallo 1D:
$115.34
$127.31
Intervallo di 1 settimana:
$108.63
$133.06
Portata 52W:
$18.23
$151.18
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Nome
Palvella Therapeutics Inc
Settore
Industria
Telefono
(484) 253-1461
Indirizzo
353 W. LANCASTER AVENUE, WAYNE
Compare PVLA vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
123.46 | 1.77B | 1.30M | -41.72M | -22.82M | -3.7071 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Iniziato | Mizuho | Outperform |
| 2025-12-05 | Iniziato | BTIG Research | Buy |
| 2025-12-04 | Iniziato | Craig Hallum | Buy |
| 2025-11-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-09-09 | Iniziato | Oppenheimer | Outperform |
| 2025-08-06 | Iniziato | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-04-09 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-26 | Iniziato | Stifel | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-20 | Iniziato | Canaccord Genuity | Buy |
| 2025-02-05 | Iniziato | TD Cowen | Buy |
| 2024-12-26 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-03-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | Iniziato | Robert W. Baird | Outperform |
| 2018-03-19 | Iniziato | Evercore ISI | Outperform |
| 2018-03-19 | Iniziato | Jefferies | Buy |
| 2018-01-16 | Reiterato | H.C. Wainwright | Buy |
| 2017-05-30 | Iniziato | Rodman & Renshaw | Buy |
| 2016-08-05 | Ripresa | ROTH Capital | Buy |
| 2015-08-12 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-07-27 | Iniziato | Oppenheimer | Outperform |
| 2015-07-22 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Palvella Therapeutics Inc Borsa (PVLA) Ultime notizie
Breakout Move: What makes Palvella Therapeutics Inc stock attractive today2026 Selloffs & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Palvella Appoints McDonough as SVP of Market Access, Patient Services - MyChesCo
Can Palvella Therapeutics Inc lead its sector in growthPortfolio Update Summary & Safe Entry Zone Identification - baoquankhu1.vn
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Palvella Therapeutics, Inc. (PVLA) stock price, news, quote and history - Yahoo Finance UK
Rare disease breakthrough? Palvella reports strong phase 2 results - MSN
HC Wainwright Brokers Decrease Earnings Estimates for PVLA - MarketBeat
Lifesci Capital Brokers Decrease Earnings Estimates for PVLA - MarketBeat
What is HC Wainwright's Estimate for PVLA Q1 Earnings? - MarketBeat
Palvella Therapeutics (PVLA) price target increased by 15.78% to 224.97 - MSN
Palvella’s Phase III Success And Fast Track Status Test Current Valuation - finance.yahoo.com
Mizuho reiterates Palvella Therapeutics stock rating on pipeline By Investing.com - Investing.com Canada
Chardan Raises Price Target on Palvella Therapeutics to $240 From $210, Keeps Buy Rating - MarketScreener
US Stocks Recap: What makes Palvella Therapeutics Inc stock attractive todayEarnings Overview Summary & Daily Stock Trend Reports - baoquankhu1.vn
Palvella Hire Highlights QTORIN Launch Plans And Deep Rare Skin Focus - Sahm
Chardan raises Palvella stock price target to $240 on pipeline progress - Investing.com Canada
Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $240.00 - MarketBeat
Palvella Highlights 2025 Results and SELVA Phase 3 Progress - TipRanks
Oppenheimer raises Palvella Therapeutics price target on valuation By Investing.com - Investing.com India
Stifel reiterates Buy rating on Palvella stock, $250 target By Investing.com - Investing.com Canada
Oppenheimer raises Palvella Therapeutics price target on valuation - Investing.com
Palvella Therapeutics Announces Positive Phase 3 Results for QTORIN Rapamycin, Prepares NDA Submission and U.S. Launch for Rare Skin Disease Therapies - Minichart
Palvella Therapeutics, Inc. (PVLA) Reports FY2025 Earnings - AlphaStreet
Palvella Therapeutics Q4 2025 Earnings Call Transcript - marketbeat.com
Palvella Therapeutics (NASDAQ:PVLA) Trading 14.4% HigherShould You Buy? - MarketBeat
PVLA: Positive phase III data, pipeline expansion, and $230M financing position for 2026 NDA submission - TradingView
PALVELLA THERAPEUTICS ($PVLA) Releases Q4 2025 Earnings, Stock Rises - Quiver Quantitative
PVLA: Positive phase III data, pipeline growth, and $230M financing position for 2027 FDA approval - TradingView
Palvella Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Palvella Therapeutics QTORIN Rapamycin: Novel Treatment Advancements for Rare Skin Diseases and Vascular Malformations - Minichart
Palvella Therapeutics Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Palvella Therapeutics’ Q4 2025 results showcase strong clinical progress - Investing.com
European Patent Office grants Palvella patent for QTORIN rapamycin - MSN
Palvella Therapeutics (NASDAQ:PVLA) Issues Quarterly Earnings Results, Misses Expectations By $0.13 EPS - MarketBeat
OS Therapies Incorporated (OSTX) Reports FY2025 Earnings - AlphaStreet
Palvella 10-K: $0 Revenue, Net Loss $41.7M — Operating Loss $38.6M - TradingView
Palvella Therapeutics (NASDAQ: PVLA) leans on QTORIN data in rare skin diseases - Stock Titan
Palvella (NASDAQ: PVLA) wins Phase 3 QTORIN data and $230M raise - Stock Titan
Palvella Therapeutics reports full year 2025 financial results and provides corporate update - marketscreener.com
Palvella Therapeutics Reports Full Year 2025 Financial Results And Provides Corporate Update - TradingView
Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update - The Manila Times
Palvella Therapeutics: Q4 Earnings Snapshot - Barchart.com
Earnings Flash (PVLA) Palvella Posts 2025 Loss $3.71 a Share, vs. FactSet Est of $3.57 Loss - MarketScreener
Palvella announces publication on lymphatic malformation subtypes By Investing.com - za.investing.com
How does Palvella Therapeutics Inc compare to its peersMarket Growth Report & Verified Entry Point Signals - baoquankhu1.vn
Palvella Therapeutics Highlights Continued Progress across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting - MarketScreener
Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations - Bitget
Palvella announces publication on lymphatic malformation subtypes - Investing.com
Palvella presents porokeratosis study data at dermatology meeting By Investing.com - Investing.com Australia
Palvella Therapeutics Inc Azioni (PVLA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):